Insights
Search Results
Client Highlights
3.31.26
Wilson Sonsini Advises NexCure on $19 Million Series A Financing
On March 5, 2026, NexCure, a healthcare company with a mission to deliver CAR-T and other clinically intensive treatments in community-based outpatient settings, launched with a $19 million Series A financing. The financing was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures. Wilson Sonsini Goodrich & Rosati advised NexCure on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Urgently on Acquisition by Agero
On March 13, 2026, Agero, a software-enabled driver safety services and technology company, announced that it has entered into an agreement to acquire Urgent.ly (Urgently), a digital software platform that provides roadside and mobility assistance, for a cash price of $5.50 per share. The tender offer and merger are expected to close by the end of May 2026, subject to satisfaction of customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Urgently on the transaction.
Client Highlights
3.18.25
Wilson Sonsini Advises DispatchHealth on Merger with Medically Home
On March 18, 2025, DispatchHealth, a leading provider of high-acuity, in-home medical care for people experiencing serious health concerns, and Medically Home, an established hospital-at-home technology enablement model for health systems and physician groups to safely provide emergency and hospital-level care at home for qualified patients, announced that they have entered into a definitive agreement to merge. The merger creates the country's most comprehensive provider of advanced medical care at home. Wilson Sonsini Goodrich & Rosati advised DispatchHealth on the transaction.
Once the deal closes, Medically Home will become part of DispatchHealth. The combined entity will extend care into the homes of patients across 50 major metropolitan areas in partnership with nearly 40 health systems, as well as most major health plans and value-based care entities. The merger is expected to close mid-year 2025, subject to customary closing conditions and regulatory approvals.
The Wilson Sonsini team that advised DispatchHealth on the transaction included Jason Breen, Matt Dubofsky, Brian Chan, and Leah Hengemuhle.
For more information, please see the companies’ news release.
Once the deal closes, Medically Home will become part of DispatchHealth. The combined entity will extend care into the homes of patients across 50 major metropolitan areas in partnership with nearly 40 health systems, as well as most major health plans and value-based care entities. The merger is expected to close mid-year 2025, subject to customary closing conditions and regulatory approvals.
The Wilson Sonsini team that advised DispatchHealth on the transaction included Jason Breen, Matt Dubofsky, Brian Chan, and Leah Hengemuhle.
For more information, please see the companies’ news release.
Client Highlights
9.19.24
Wilson Sonsini Advises GC Therapeutics on $65 Million Series A
On September 19, 2024, GC Therapeutics (GCTx), a biopharmaceutical company created to scale and unlock the next generation of cell therapy-based medicines, launched and announced the successful completion of a $65 million Series A financing led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management, and Pear VC, bringing the total capital raised by GCTx to $75 million. Wilson Sonsini Goodrich & Rosati advised GC Therapeutics on the transaction.
Client Highlights
2.07.24
Wilson Sonsini Advises ThayerMahan on $20 Million in Additional Series C Funding
On January 9, 2024, ThayerMahan, a world leader in autonomous maritime surveillance solutions, closed $20 million in follow-on Series C funding led by Hanwha Asset Management. Existing investors, including MC2, AE Industrial, I Squared Capital, and Yellow Sub Funding participated pro rata in the round. The investment follows a $30 million Series C investment led by MC2 in April 2023. Wilson Sonsini Goodrich & Rosati advised ThayerMahan on the transaction.
"I am very excited by our new partnership with Hanwha Asset Management, a global leader in alternative energy and maritime services,” said Mike Connor, ThayerMahan Chairman and CEO. "We have a shared vision for how emerging acoustic and AI technologies can advance maritime commerce and the global Blue Economy. Hanwha's industry expertise, market presence, and ambitious management team make the organization a great partner for ThayerMahan as it continues to develop its capabilities and expand operations to Asia. I want to thank our existing investors who participated in the round to maintain their pro rata ownership. Their continued partnership is critical to our success, and we look forward to creating more value together in the coming years."
The Wilson Sonsini team that advised ThayerMahan on the transaction included Mark Fitzgerald, Stephen Heifetz, Leah Hengemuhle, Tamara Labanowski, Andrew Savage, and Daniel Jordan.
"I am very excited by our new partnership with Hanwha Asset Management, a global leader in alternative energy and maritime services,” said Mike Connor, ThayerMahan Chairman and CEO. "We have a shared vision for how emerging acoustic and AI technologies can advance maritime commerce and the global Blue Economy. Hanwha's industry expertise, market presence, and ambitious management team make the organization a great partner for ThayerMahan as it continues to develop its capabilities and expand operations to Asia. I want to thank our existing investors who participated in the round to maintain their pro rata ownership. Their continued partnership is critical to our success, and we look forward to creating more value together in the coming years."
The Wilson Sonsini team that advised ThayerMahan on the transaction included Mark Fitzgerald, Stephen Heifetz, Leah Hengemuhle, Tamara Labanowski, Andrew Savage, and Daniel Jordan.
Client Highlights
4.18.23
Wilson Sonsini Advises ThayerMahan on $30 Million Series C
On April 13, 2023, ThayerMahan, a world leader in autonomous maritime surveillance solutions, announced the closing of a $30 million Series C round, led by the MC2 Security Fund (MC2). Other notable new investors in the round included I Squared Capital, Ducenta Squared Asset Management, and Compass Partners, along with additional participation by existing investors AE Industrial Partners, Hegemon Capital, and an affiliate of RiverPark Ventures. Wilson Sonsini Goodrich & Rosati advised ThayerMahan on the transaction.
Client Highlights
8.20.21
Wilson Sonsini Advises RTW Investments on Artios Pharma’s $153 Million Series C Financing
On July 27, 2021, Artios Pharma, a leading DNA Damage Response company, announced the completion of a US$153 million (£110 million) Series C financing to fund further development of its promising clinical-stage pipeline. The financing was co-led by Omega Funds and TCG X. Additional investors include Avidity Partners, Invus, Deep Track Capital, Sofinnova Partners, Tetragon Financial Group, RTW Investments, Soleus Capital, Piper Heartland Healthcare Capital, CaaS Capital Management, and Schroders Capital. These new investors join existing investors Arix Bioscience, SV Health Investors, Andera Partners, Life Sciences Partners, M Ventures, Pfizer Ventures, IP Group, and Novartis Venture Fund who also continue to support Artios through their participation. Wilson Sonsini Goodrich & Rosati represented RTW Investments in the transaction.
Client Highlights
7.27.21
Wilson Sonsini Represents Totient in Acquisition by AbSci
On June 14, 2021, AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition of Totient, a discovery company harnessing human immune responses to identify novel antibodies and their therapeutic targets. The acquisition adds antibody and target discovery technology to AbSci's platform for therapeutic protein design and biomanufacturing optimization. Wilson Sonsini Goodrich & Rosati represented Totient in the transaction.
Client Highlights
5.20.21
Wilson Sonsini Represents ThayerMahan in Acquisition of Wingman Defense
On May 19, 2021, ThayerMahan, Inc., a world leader in autonomous maritime security solutions, announced its acquisition of Wingman Defense, an artificial intelligence start-up. Wilson Sonsini Goodrich & Rosati represented ThayerMahan in the transaction.
Client Highlights
2.08.21
Wilson Sonsini Advises NeuroCycle Therapeutics on Acquisition by Engrail Therapeutics
On February 2, 2021, Engrail Therapeutics announced that it has acquired NeuroCycle Therapeutics, a company focused on sub-type selective GABA-A modulation. The acquisition strengthens Engrail’s presence in the GABA-A space and provides a strong platform for initiation of clinical trials with multiple assets in 2021. Wilson Sonsini Goodrich & Rosati represented NeuroCycle Therapeutics in the transaction.
Client Highlights
8.10.20
Wilson Sonsini Represents ThayerMahan in Acquisition of Ocean Acoustical Services and Instrumentation Systems
On August 3, 2020, ThayerMahan announced its acquisition of Ocean Acoustical Services and Instrumentation Systems (OASIS). Founded in 2016, ThayerMahan has rapidly grown into an industry leader in autonomous marine sensor/system solutions and has developed patented technology solutions in acoustics, electronic sensing, autonomy, communications and data management while providing unique MDA (Maritime Domain Awareness) solutions to a diverse body of clients in government, industry, and academia. ThayerMahan has worked closely with OASIS in the development of cutting-edge acoustic sensor and processing technologies.
Client Highlights
6.15.20
Wilson Sonsini Advises Lexent Bio in Acquisition by Foundation Medicine
On June 12, Foundation Medicine (member of the Roche Group), a Massachusetts-based molecular information company providing genomic profiling services that help personalize cancer care, announced that it had completed the acquisition of Lexent Bio, Inc. Wilson Sonsini Goodrich & Rosati advised Lexent Bio in the transaction and has advised Lexent Bio since its formation. The total potential consideration was undisclosed, but included an upfront payment as well as contingent milestone payments.